Trexquant Investment LP Purchases 59,241 Shares of LivaNova PLC (NASDAQ:LIVN)

Trexquant Investment LP lifted its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 139.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 101,653 shares of the company's stock after acquiring an additional 59,241 shares during the quarter. Trexquant Investment LP owned approximately 0.19% of LivaNova worth $4,708,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of LIVN. Artisan Partners Limited Partnership bought a new stake in LivaNova in the fourth quarter valued at approximately $21,340,000. Vanguard Group Inc. lifted its holdings in LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after purchasing an additional 265,291 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in LivaNova during the 4th quarter valued at $9,645,000. Wellington Management Group LLP bought a new position in LivaNova during the fourth quarter worth $8,897,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of LivaNova by 95.7% during the 4th quarter. JPMorgan Chase & Co. now owns 387,772 shares of the company's stock worth $17,958,000 after buying an additional 189,665 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

LIVN has been the subject of several research reports. Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Barclays decreased their price target on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research note on Friday, March 7th. Stifel Nicolaus cut their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Finally, Wolfe Research cut shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $61.17.

LivaNova Trading Down 5.3 %

Shares of NASDAQ:LIVN traded down $1.88 during mid-day trading on Thursday, reaching $33.84. 138,769 shares of the company's stock were exchanged, compared to its average volume of 621,045. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 80.56 and a beta of 0.90. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $64.48. The business's fifty day moving average price is $41.93 and its 200-day moving average price is $47.56. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.